
Topic
PD-L1
Podcasts
Tumor Board # 87Oct 27, 2026Diagnosis & Management of Advanced HER2-Negative Upper GI Cancers

Five years ago, first-line treatment for advanced HER2-negative gastroesophageal cancer meant chemotherapy; today claudin 18.2, PD-L1, and mismatch repair status shape the plan, often for a patient who cannot afford to wait for the results. On this episode of the BackTable GI Oncology Creator Weekend™, host Dr. Kate Baker interviews medical oncologists Dr. Ronan Hsieh and Dr. Dani Castillo about the diagnosis and management of advanced HER2-negative upper GI cancers. They discuss the biomarker workup at diagnosis, next-generation sequencing and liquid biopsy, when to biopsy metastatic sites, and why both guests start chemotherapy before every result is available.
Tumor Board # 44Jan 20, 2026ESMO Update: Advances in Upper GI Malignancies

The FLOT regimen is the standard-of-care for upper gastroesophageal malignancies, but what if there were other drug combinations or perioperative strategies that could further improve outcomes? In Part II of our ESMO 2025 recap, medical oncologists Dr. Jun Gong and Dr. Jonathan Mizrahi cover emerging studies and treatments in gastroesophageal cancers.
Tumor Board # 32Oct 28, 2025Understanding Keynote-689: Immunotherapy for Head & Neck Cancer

While the standard for adjuvant head and neck cancer treatment hasn't changed since 2004, a new trial using perioperative pembrolizumab is forcing clinicians to rethink their entire workflow, starting with diagnosis. In this episode of the BackTable Podcast, head and neck surgical oncologist Dr. Adam Luginbuhl is joined by colleagues Dr. Dylan Roden and Dr. Ravindra Uppaluri to discuss the implementation and implications of the Keynote-689 trial, which introduced neoadjuvant and adjuvant immunotherapy for locally advanced head and neck cancer.